2018
EV-201 study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.
Rosenberg J, Heath E, O'Donnell P, Hahn N, Balar A, Gartner E, Melhem-Bertrandt A, Petrylak D. EV-201 study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy. Journal Of Clinical Oncology 2018, 36: tps542-tps542. DOI: 10.1200/jco.2018.36.6_suppl.tps542.Peer-Reviewed Original ResearchObjective response rateMetastatic urothelial cancerCheckpoint inhibitorsUrothelial cancerMicrotubule-disrupting agent monomethyl auristatin EMulticenter phase 2 studyOngoing phase 1 studiesImmune checkpoint inhibitor therapyAntitumor activityCheckpoint inhibitor therapyDisease control ratePhase 2 doseSafety/tolerabilityTreatment-related AEsImmune checkpoint inhibitorsPhase 2 studyMajority of patientsPhase 1 studyUrinary tract infectionTreatment of patientsTransitional cell carcinomaAssessment of durationMonomethyl auristatin EWarrants further investigationAntibody-drug conjugates
2007
Risk Factors for the Development of Bone Metastases in Prostate Cancer
Petrylak D. Risk Factors for the Development of Bone Metastases in Prostate Cancer. European Urology Open Science 2007, 6: 677-682. DOI: 10.1016/j.eursup.2007.03.005.Peer-Reviewed Original ResearchAndrogen deprivation therapyBone metastasesEarly prostate cancerProstate cancerRisk factorsEarly identificationDisease courseBone lossHigher baseline PSA levelsProstate-specific antigen levelChronic bone painHigh PSA velocityBaseline PSA levelsSpinal cord compressionMajority of patientsAdvanced prostate cancerBone health issuesBone health maintenanceBone mineral densityBone painCord compressionPalliative radiotherapyPSA velocitySkeletal complicationsPathologic fracture